BioMarin Will Report Breadth of Innovative Development Pipeline at Analyst, Investor Day

BioMarin Pharmaceutical Inc.

will host an Analyst and Investor Day from 8am (ET) to 1pm (ET) on Wednesday, December 10, 2014 at The Plaza Hotel. BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. In addition, the leadership team will highlight its recently announced intention to acquire Prosensa Holding N.V. BioMarin speakers scheduled to present include: * Jean-Jacques Bienaimé, Chief Executive Officer * Hank Fuchs, M.D., Chief Medical Officer * Dan Spiegelman, Chief Financial Officer * Jeff Ajer, Chief Commercial Officer * Barrie Carter, Ph.D., Vice President, Vector Biology * Wolfgang Dummer, M.D., Ph.D., Vice President, Clinical Development * Dave Jacoby, M.D. Ph.D., Executive Group Medical Director * Leonid Katz, M.D., Senior Medical Director * Len Post, Ph.D., Group Vice President, Chief Scientific Officer External key opinion leaders scheduled to present include: * Cary Harding, M.D., Professor of Molecular and Medical Genetics and Pediatrics at Oregon Health and Science University * Alfried Kohlschütter, M.D., Professor of Pediatrics, Department of Pediatrics, University Medical Center Eppendorf, Germany * Craig McDonald, M.D., Professor and Chair, Department of Physical Medicine and Rehabilitation, School of Medicine, U.C. Davis Health System * Glenn Pierce, M.D., Ph.D., former Chief Medical Officer and Senior Vice President of Biogen Idec Hemophilia Therapeutic Area * Cathleen Raggio, M.D., Attending Orthopedic Surgeon, Co-Director, The Kathryn O. and Alan C. Greenberg Center for Skeletal Dysplasias at Hospital for Special Surgery, New York Interested parties may access a live audio webcast and slides of the presentations via the investor section of the BioMarin website, www.BMRN.com. A replay of the meeting will be archived on the site for at least one week. Dial-in information for those not able to access the webcast; U.S. / Canada Dial-in Number: (877) 303-6313 International Dial-in Number: (631) 813-4734 Conference ID: 30219509